Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Academic Article
Publication Date:
2014
Iris type:
1.1 Articolo in rivista
List of contributors:
Confavreux, C; O'Connor, P; Comi, Giancarlo; Freedman, Ms; Miller, Ae; Olsson, Tp; Wolinsky, Js; Bagulho, T; Delhay, Jl; Dukovic, D; Truffinet, P; Kappos, L.
Published in: